

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SoftMedx Healthcare Limited

京玖醫療健康有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 648)

RESULTS OF FOLLOW-UP REVIEW

References are made to the announcement (“**Announcement**”) of SoftMedx Healthcare Limited (the “**Company**”) dated 31 October 2025. Terms used in this announcement shall have the same meaning as those defined in the Announcement.

RESULTS OF THE FOLLOW-UP REVIEW

As disclosed in the Announcement, the resumption of trading in the shares of the Company is subject to the following Resumption Conditions (“**Resumption Conditions**”):

Resumption Condition 1: The Company shall publish the Announcement.

Resumption Condition 2: The Company undertakes to (a) procure the IC Consultant to perform a follow-up review on 30 September 2025 to assess whether the recommendations outlined in the IC Report have been properly implemented by the Company (“**Follow-up Review**”) and (b) procure the IC Consultant to submit a report following the Follow-up Review (“**Follow-up Review Report**”) to the Company and the Commission for concurrent review.

Resumption Condition 3: The Company shall publish this announcement regarding the results of the Follow-up Review Report.

As stated in the Announcement, the Company is of the view that Resumption Condition 1 has been fulfilled.

As at the date of this announcement, the Company has procured the IC Consultant to perform the Follow-up Review and submitted the Follow-up Review Report to the Company and the Commission. The IC Consultant has confirmed in the Follow-up Review Report that the Company has implemented all the recommendations set out in the IC Report where applicable with no exception noted. A summary of the IC Consultant's recommendations was stated in the Announcement.

Accordingly, the Company announces that the remaining Resumption Condition 2 and Resumption Condition 3 have been fulfilled and, as such, all the Resumption Conditions have been fulfilled.

For and on behalf of the board of
SoftMedx Healthcare Limited
Lam Sung Him Gaston
Company Secretary

Hong Kong, 2 July 2026

As at the date of this announcement, the board of the Company comprises Mr. Lin Pinzhuo as executive director; and Mr. Ngok Ho Wai, Ms. Tang Cuihuen and Mr. Yiu Chun Wing as independent non-executive directors.